GLOW: Three Peptides, Three Mechanisms, Zero Combination Trials

The short version

GLOW is not one molecule — it is a combination of three separately studied research peptides: GHK-Cu (a copper-carrying tripeptide), BPC-157 (a stomach-derived repair peptide), and TB-500 (an actin-binding fragment of thymosin beta-4). The rationale for combining them is that each targets a different piece of tissue repair: GHK-Cu for the collagen/elastin matrix, BPC-157 for blood-vessel growth, TB-500 for cell movement. That rationale is mechanistically plausible, and every individual claim below is backed by a cited study — but no study has ever tested the three-peptide combination itself, in any species, at any dose. Everything on this page describes what the three components do separately. GLOW is sold as a research chemical, is not FDA-approved, and — because it contains TB-500 — is off-limits under anti-doping rules for any tested athlete. Nothing here is a recommended dose or a use in a person.

What it is

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine (C14H23CuN6O4+, molecular weight approximately 402.9 Da, CAS 89030-95-5) — a naturally occurring human tripeptide that declines with age and, complexed with copper, drives matrix synthesis. BPC-157 is a synthetic 15-residue peptide (GEPPPGKPADDAGLV, molecular weight approximately 1419 Da) derived from a fragment of a gastric protective protein. TB-500 is the acetylated 7-residue fragment Ac-LKKTETQ (molecular weight approximately 889 Da) of the 43-residue protein thymosin beta-4. Formulations vary by supplier; a commonly cited research-label ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, though no ratio has been validated in a controlled study — "commonly cited" describes market convention, not evidence. Because the three peptides have different molecular sizes and clearance rates, a single co-formulated injection combines three different pharmacokinetic profiles that have never been characterized together.

How it works

The combination thesis rests on three non-overlapping mechanisms. GHK-Cu acts as a copper chaperone and matrix-remodeling signal, driving dermal fibroblasts to synthesize collagen, elastin, and glycosaminoglycans while rebalancing matrix metalloproteinases. BPC-157 is cytoprotective and pro-angiogenic: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS signaling axis, increasing vessel density in both chick and rodent models ^[3]. TB-500 supplies the third leg — as thymosin beta-4's actin-binding fragment, it is associated (via the parent protein) with faster cell migration, angiogenesis, and reduced scar formation. Layered together, the thesis is: build the matrix (GHK-Cu), feed it blood supply (BPC-157), and move repair cells into the gap faster (TB-500). It is a coherent story on paper. It has not been tested as a combined intervention in any published trial, in any species.

What the research shows

A 2026 Sports Medicine narrative review — one of the only sources to discuss GHK-Cu, BPC-157, and TB-500 together — concludes that unapproved peptides in this category show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, describing a "gray market" of such compounds operating largely outside regulatory oversight ^[1]. That framing sets the ceiling for everything below it.

BPC-157. A 2025 narrative review found only three small human pilot studies of BPC-157 (intra-articular knee pain, interstitial cystitis, and an intravenous safety/pharmacokinetics study), reporting no adverse effects but concluding the compound remains investigational pending larger trials ^[2]. Mechanistically, BPC-157 increased VEGFR2 mRNA and protein expression and activated the VEGFR2-Akt-eNOS pathway, raising vessel density in chick chorioallantoic membrane and rat hind-limb ischemia models, and in human vascular endothelial cells in vitro ^[3].

GHK-Cu. GHK is present naturally in human plasma, saliva, and urine, and its levels decline with age; as the copper complex, it stimulates collagen, dermatan sulfate, chondroitin sulfate, and decorin synthesis and has been linked to firmer, less-lined skin in human studies ^[4]. A separate review catalogs GHK-Cu's broader tissue-remodeling effects — increased collagen, elastin, VEGF, FGF-2, and nerve growth factor, alongside suppressed TGF-beta-1 and TNF-alpha — across multiple human and animal studies ^[5].

Reported effects, cautions & safety

Community and clinic-blog accounts of the GLOW stack are anecdotal, not clinical evidence — there is no controlled study of the three-peptide blend, and none of what follows comes with a verified dose. The most frequently described benefit is the effect the blend is named for: a brighter, more even-looking complexion within a few weeks, generally credited to the GHK-Cu component, alongside smoother texture and, in longer accounts (eight to twelve weeks), softer-looking fine lines. A separate cluster of reports — carried over from the BPC-157/TB-500 recovery-stack literature the blend builds on — describes faster-feeling healing of wounds and scars and easier recovery from a nagging tendon or joint issue. On the adverse side, a brief sting or burn at injection (attributed to the copper complex) is the most consistently mentioned downside, followed by injection-site redness or itching, early fatigue or headache, and — less often — facial flushing, a metallic taste, or mild bloating and nausea.

The cited cautions are firmer than the anecdotes. Athletes subject to anti-doping testing should treat GLOW as off-limits: TB-500 (thymosin beta-4) sits on the WADA Prohibited List at all times, and using GLOW implicates that rule regardless of the skin-focused marketing ^[1][13]. People with an active or recent cancer should weigh the blend's pro-angiogenic components carefully — BPC-157 and TB-500 both promote new blood-vessel growth, a theoretical concern for tumors that depend on their own blood supply ^[2][3]. People with Wilson's disease or another copper-overload condition should avoid the GHK-Cu component specifically, since it is designed to deliver copper into tissue ^[4]. And because the blend itself is untested, its three components' mismatched clearance rates have never been characterized together in a single formulation ^[1].

Where it fits in soft-tissue and connective-tissue repair research

GLOW is this desk's combination case study — what happens when three separately reasonable mechanisms are stacked without being tested as a stack. Its TB-500 component is the same actin-binding fragment covered in depth on TB-500's own page, where the evidence for cell migration and wound re-epithelialization is considerably more developed. Its BPC-157 component supplies the vascular leg that KPV's gut-focused anti-inflammatory mechanism does not attempt. Reading GLOW alongside KPV and TB-500 shows the range of this desk's frame: matrix-plus-vessel-plus-migration in one combination product, an anti-inflammatory tripeptide with a single organ focus, and a widely studied migration fragment used alone. See the comparison page for the direct, dimension-by-dimension read.